Background: This was a phase 1, dose-escalation open-label trial to evaluate the safety and immunogenicity of MVC-COV1901, SARS-CoV-2 S-2P protein vaccine adjuvanted with aluminum hydroxide CpG 1018.
Methods: 45 healthy adults from 20 49 years age were be administered two vaccinations MVC-COV1901 in doses 5 μg, 15 or 25 μg spike at 28 days apart. There participants each dose group; all follo...